Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 346 to 360 of 735 results for adult social

  1. Mega Soft Patient Return Electrode for use during monopolar electrosurgery (HTG290)

    Evidence-based recommendations on Mega Soft Patient Return Electrode for use during monopolar electrosurgery.

  2. Omalizumab for treating severe persistent allergic asthma (TA278)

    Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.

  3. Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)

    Evidence-based recommendations on abrocitinib (Cibinqo), tralokinumab (Adtralza) or upadacitinib (Rinvoq) for treating moderate to severe atopic dermatitis.

  4. Head injury: assessment and early management (NG232)

    This guideline covers assessment and early management of head injury in babies, children, young people and adults. It aims to ensure that people have the right care for the severity of their head injury, including direct referral to specialist care if needed.

  5. Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)

    Evidence-based recommendations on mavacamten (Camzyos) for symptomatic obstructive hypertrophic cardiomyopathy.

  6. Individual versus group CBT for children and young people with social anxiety disorder:- What is the clinical and cost effectiveness of individual and group CBT for children and young people with social anxiety disorder?

    with social anxiety disorder:- What is the clinical and cost effectiveness of individual and group CBT for children and young people...

  7. Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) with cyclophosphamide, doxorubicin and prednisone for untreated systemic anaplastic large cell lymphoma in adults.

  8. Vismodegib for treating basal cell carcinoma (TA489)

    Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma in adults.

  9. Stage 5: discharge and transferring care

    Our guidance helps you hand over care and ensure people are safely transitioned out of the virtual ward environment.

  10. Physical activity and the environment (NG90)

    This guideline covers how to improve the physical environment to encourage and support physical activity. The aim is to increase the general population’s physical activity levels.

  11. Diagnostics advisory committee members

    Biographies for all current members of the diagnostics advisory committee.

  12. Diagnostics advisory committee members

    Biographies for all current members of the diagnostics advisory committee.

  13. Skin cancer prevention (PH32)

    This guideline covers new buildings and communal outdoor areas. The aim is to ensure there are enough shady areas to protect people from overexposure to the sun.

  14. Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173)

    This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living. The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management.

  15. Transition support for young adults:- What approaches to providing transition support for those who move from child to adult services are effective and/or cost-effective?

    Transition support for young adults:- What approaches to providing transition support for those who move from child to...